生命科学资讯
生物技术与制药领域的最新动态
Beam Therapeutics' new PKU program; Protara's bladder cancer data
Abcuro drug fails muscle weakness trial, development to continue
Immedica wins accelerated approval for once-rejected rare disease drug
New biotech Slate Medicines raises $130M for migraine drug from China
诺和诺德的三重G在肥胖症领域与礼来竞争激烈，但可能将晚于对手上市。
Novo Nordisk’s triple-G is competitive with Lilly in obesity, but likely to be second to market
辉瑞收购中国药企信达生物GLP-1药物权益，加码代谢疾病领域布局。
Pfizer buys China rights to Sciwind’s approved GLP-1 drug in metabolic push
Hims公布2025年财报，透露GLP-1药丸决策细节
Hims reports 2025 earnings, shares details on GLP-1 pill decisions
安斯泰来以2.4亿美元现金收购Vir前列腺癌药物。
Astellas pays $240M cash for Vir's prostate cancer drug
QurAlis公司ALS药物早期显现积极信号，但疑问犹存。
QurAlis' ALS drug sees early positive signal, but questions remain
瑞士火箭公司收购华大基因子公司Complete Genomics，紧随《生物安全法案》之后
Swiss Rockets buys MGI subsidiary Complete Genomics after Biosecure Act
堡垒生物科技将以2.05亿美元出售优先审评券
Fortress to sell priority review voucher for $205M
美国食品药品监督管理局发布期待已久的个体化治疗新途径指南。
FDA unveils long-awaited guidance on new pathway for individualized therapies
旗舰公司Generate瞄准纳斯达克上市，估值目标超20亿美元
Flagship's Generate targets $2B+ valuation with Nasdaq IPO
艾伯维斥资3.8亿美元在芝加哥建设肥胖与神经科学原料药设施。
AbbVie budgets $380M for obesity and neuroscience API facilities in Chicago
前沿与港湾分别与葛兰素史克、Solstice达成许可协议
Frontier, Harbour do licensing deals with GSK, Solstice
联邦实验为数字健康开辟新市场——前提是成功
A federal experiment opens up a new market for digital health — if it works
罗氏将停止针对杜氏肌营养不良症的骨骼健康治疗研究。
Roche to stop work on bone health treatment for Duchenne
罗氏将停止针对杜氏肌营养不良症的骨健康治疗研究——终点新闻
Roche to stop work on bone health treatment for Duchenne - Endpoints News
默克重组；黑石集团将为强生药物试验提供资金。
Merck reorganizes; Blackstone to fund trials for J&J drug